Oral pharmabiotic tablet formulations

Buse Kandur; Timuçin Uğurlu; Erkan Rayaman; Sevinç Şahbaz

Oral pharmabiotic tablet formulations

Abstract

Pharmabiotic is a unique and recent term used to describe formulations containing probiotics. Pharmabiotics are probiotics prepared in a pharmaceutical form used to treat diseases and disorders by making physicochemical changes in human health. Probiotics, prebiotics, and synbiotics are included in this scope, and enzobiotics, which are a rising class of supplements, should be evaluated in this context, as they are a subspecies of synbiotics. Pharmabiotics, unlike nutribiotics, do not necessarily contain live microorganisms. The best examples of these are paraprobiotics and postbiotics. Tablet formulations are suitable dosage forms for pharmabiotics due to their redundant superiority over other solid dosage forms. Tablets are frequently preferred because they can be produced at low cost, are easily transported, and modified, are suitable for large-scale production, and are more stable than other dosage forms. Considering the examples in the literature and the definition of pharmabiotic, several tablet formulations can be mentioned as pharmabiotics. They can be divided into conventional uncoated tablets, chewable tablets, and effervescent tablets. With recent studies, this classification has expanded, and buccal mucoadhesive tablets, ODTs (orally disintegrating tablets) and FDTs (fast disintegrating tablets), layered/multi-layered tablets, and tablets within tablets have also taken their place in the classification. This article focuses on oral tablet formulations that can be classified as pharmabiotics.

Keywords

References

[1] FAO/WHO. Probiotics in food. 2006. Food and Agriculture Organization of the United Nations/World Health Organization, London, Ontario. https://www.fao.org/3/a0512e/a0512e.pdf, (accessed August 25, 2023).
[2] Wang G, Chen Y, Xia Y, Song X, Ai L. Characteristics of probiotic preparations and their applications. Foods. 2022; 11(16): 2472. https://doi.org/10.3390/foods11162472.
[3] Fijan S. Microorganisms with claimed probiotic properties: An overview of recent literature. Int J Environ Res Public Health. 2014; 11(5): 4745–4767. https://doi.org/10.3390/ijerph110504745.
[4] Lee ES, Song EJ, Nam Y do, Lee SY. Probiotics in human health and disease: From nutribiotics to pharmabiotics. J. Microbiol. 2018; 56: 773–782. https://doi.org/10.1007/s12275-018-8293-y.
[5] Jung YO, Jeong H, Cho Y, Lee EO, Jang HW, Kim J, Nam KT, Lim KM. Lysates of a probiotic, Lactobacillus rhamnosus, can improve skin barrier function in a reconstructed human epidermis model. Int J Mol Sci. 2019; 20(17): 4289. https://doi.org/10.3390/ijms20174289.
[6] Teame T, Wang A, Xie M, Zhang Z, Yang Y, Ding Q, Gao C, Olsen RE, Ran ,5C, Zhou Z. Paraprobiotics and postbiotics of probiotic Lactobacilli, their positive effects on the host and action mechanisms: A Review. Front Nutr. 2020; 7: 570344. https://doi.org/10.3389/fnut.2020.570344.
[7] Giron F, Quigley EMM. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders: A clinical perspective. J Neurogastroenterol Motil. 2018; 24(3): 355–366. https://doi.org/10.5056/jnm18004.
[8] Johnson-Henry KC, Sherman PM. Exploring frontiers of new probiotic and pharmabiotic therapies. Nutrafoods. 2008; 7(2/3): 27–36.

[9] Cunningham M, Azcarate-Peril MA, Barnard A, Benoit V, Grimaldi R, Guyonnet D, Holscher HD, Hunter K, Manurung S, Obis D, Petrova MI, Steinert RE, Swanson KS, van Sinderen D, Vulevic J, Gibson GR. Shaping the future of probiotics and prebiotics. Trends Microbiol. 2021; 29(8): 667–685. https://doi.org/10.1016/j.tim.2021.01.003.
[10] Remes-Troche JM, Coss-Adame E, Valdovinos-Díaz MA, Gómez-Escudero O, Icaza-Chávez ME, Chávez-Barrera JA, Mondragón FZ, Velasco JAVR, Aceves-Tavares GR, Lira-Pedrín MA, Cerda-Contreras E, Carmona-Sánchez RI, López HG, Ortiz RS. Lactobacillus acidophilus LB: A useful pharmabiotic for the treatment of digestive disorders. Therap Adv Gastroenterol. 2020; 13: 1–15. https://doi.org/10.1177/1756284820971201.
[11] Saxena A, Srinivasa S, Veerappan I, Jacob C, Mahaldar A, Gupta A, Rajagopal A. Enzobiotics-a novel therapy for the elimination of uremic toxins in patients with CKD (EETOX Study): A multicenter double-blind randomized controlled trial. Nutrients. 2022; 14(18): 3804. https://doi.org/10.3390/nu14183804.
[12] Meirlaen L, Levy EI, Vandenplas Y. Prevention and management with pro-, pre and synbiotics in children with asthma and allergic rhinitis: A narrative review. Nutrients. 2021; 13(3): 934. https://doi.org/10.3390/nu13030934.
[13] Erdem NB, Açıkgöz A. Probiotics and prebiotics in celiac diseases J Health Sci. 2019; 28(3): 177–181. https://doi.org/10.34108/eujhs.470781.
[14] Mazziotta C, Tognon M, Martini F, Torreggiani E, Rotondo JC. Probiotics Mechanism of action on immune cells and beneficial effects on human health. Cells. 2023; 12(1): 184. https://doi.org/10.3390/cells12010184.
[15] Guo W, Cui S, Tang X, Yan Y, Xiong F, Zhang Q, Zhao J, Mao B, Zhang H. Intestinal microbiomics and hepatic metabolomics insights into the potential mechanisms of probiotic Bifidobacterium pseudolongum CCFM1253 preventing acute liver injury in mice. J Sci Food Agric. 2023; 103: 5958–5969. https://doi.org/10.1002/jsfa.12665.
[16] James A, Ke H, Yao T, Wang Y. The role of probiotics in purine metabolism, hyperuricemia and gout: Mechanisms and interventions. Food Rev Int. 2023; 39(1): 261–277. https://doi.org/10.1080/87559129.2021.1904412.
[17] Mgbodile FC, Nwagu TNT. Probiotic therapy, African fermented foods and food-derived bioactive peptides in the management of SARS-CoV-2 cases and other viral infections. Biotechnol Rep. 2023; 38: e00795. https://doi.org/10.1016/j.btre.2023.e00795.
[18] Baral KC, Bajracharya R, Lee SH, Han HK. Advancements in the pharmaceutical applications of probiotics: Dosage forms and formulation technology. Int J Nanomed. 2021; 16: 7535–7556. https://doi.org/10.2147/IJN.S337427.
[19] Rather IA, Bajpai VK, Huh YS, Han YK, Bhat EA, Lim J, Paek WK, Park YH. Probiotic Lactobacillus sakei proBio-65 extract ameliorates the severity of imiquimod induced psoriasis-like skin inflammation in a mouse model. Front Microbiol. 2018; 9: 1021. https://doi.org/10.3389/fmicb.2018.01021.
[20] Vigani B, Faccendini A, Rossi S, Sandri G, Bonferoni MC, Grisoli P, Ferrari F. Development of a mucoadhesive in situ gelling formulation for the delivery of Lactobacillus gasseri into vaginal cavity. Pharmaceutics. 2019; 11(10): 511. https://doi.org/10.3390/pharmaceutics11100511.
[21] Lebeer S, Oerlemans EFM, Claes I, Henkens T, Delanghe L, Wuyts S, Spacova I, van den Broek MFL, Tuyaerts I, Wittouck S, De Boeck I, Allonsius C, Kiekens F, Lambert J. Selective targeting of skin pathobionts and inflammation with topically applied lactobacilli. Cell Rep Med. 2022; 3(2): 100521. https://doi.org/10.1016/j.xcrm.2022.100521.
[22] Sathikulpakdee S, Kanokrungsee S, Vitheejongjaroen P, Kamanamool N, Udompataikul M, Taweechotipatr M. Efficacy of probiotic-derived lotion from Lactobacillus paracasei MSMC 39-1 in mild to moderate acne vulgaris, randomized controlled trial. J Cosmet Dermatol. 2022; 21: 5092-5097. https://doi.org/10.1111/jocd.14971.
[23] Nader-Macías MEF, de Gregorio PR, Silva JA. Probiotic lactobacilli in formulas and hygiene products for the health of the urogenital tract. Pharmacol Res Perspect. 2021; 9(5): e00787. https://doi.org/10.1002/prp2.787.
[24] Amit-Romach E, Uni Z, Friedman M, Aizenberg I, Berkovich Z, Reifen R. A new mode of probiotic therapy: Specific targeting. J Funct Foods. 2015; 16: 386–392. https://doi.org/10.1016/j.jff.2015.04.029.
[25] Akova B, Kıvanç S.A, Kıvanç M. Antibiofilm effect of probiotic lactic acid bacteria against Bacillus spp obtained from the ocular surface. Eur Rev Med Pharmacol Sci. 2021; 25(24): 7799-7805. https://doi.org/10.26355/eurrev_202112_27626.
[26] Harikumar G, Jain S, Halagali P, Shailesh T, Deshpande PS, Kumar HS. Recent advancements in the development of probiotics as pharmaceuticals: A review. Eur Chem Bull. 2023; 12(4): 2452–2475. https://doi.org/10.31838/ecb/2023.12.si4.209.
[27] Baheti R, Mahore J, Patole V. Different formulation approaches to improve the survivability of probiotics in the digestive tract. Nov Res Microbiol J. 2023; 7(2): 1873-1896. https://doi.org/10.21608/NRMJ.2023.291832.
[28] Barajas-Álvarez P, González-Ávila M, Espinosa-Andrews H. Recent advances in probiotic encapsulation to improve viability under storage and gastrointestinal conditions and their impact on functional food formulation. Food Rev Int. 2023; 39(2): 992–1013. https://doi.org/10.1080/87559129.2021.1928691.
[29] Tran PHL, Lee BJ, Tran TTD. Strategies and formulations of freeze-dried tablets for controlled drug delivery. J Pharm. 2021; 597: 120373. https://doi.org/10.1016/j.ijpharm.2021.120373.
[30] Halacoglu M, Ugurlu T. Tablets and some equations for determination of forces affecting tablet compaction. Clin Exp Health Sci. 2015; 1. https://doi:10.5455/musbed.20150602014155.
[31] Bhowmik D, Duraivel S., Rajalakshmi AN, Kumar KPS. Tablet manufacturing processs and defects of tablets. Elixir Pharmacy. 2014; 70: 24368–24374.
[32] Markl D, Strobel A, Schlossnikl R, Bøtker J, Bawuah P, Ridgway C, Rantanen J, Rades T, Gane P, Peiponen K, Zeitler JA. Characterisation of pore structures of pharmaceutical tablets: A review. Int J Pharm. 2018; 538: 188–214. https://doi.org/10.1016/j.ijpharm.2018.01.017.
[33] Conway BR. Normal Dosage Forms. In: Goud R, editor. Pharmaceutical Manufacturing Handbook. 1st ed. North Carolina: Wiley; 2008. pp. 233–235.
[34] Sreeja V, Prajapati JB. Probiotic formulations: Application and status as pharmaceuticals-A review. Probiotics Antimicrob Proteins. 2013; 5(2): 81–91. https://doi.org/10.1007/s12602-013-9126-2.
[35] Byl E, Bladt P, Lebeer S, Kiekens F. Importance of pressure plasticity during compression of probiotic tablet formulations. Eur J Pharm Biopharm. 2019; 145: 7–11. https://doi.org/10.1016/j.ejpb.2019.10.001.
[36] Vorländer K, Kampen I, Finke JH, Kwade A. Along the process chain to probiotic tablets: Evaluation of mechanical impacts on microbial viability. Pharmaceutics. 2020; 12(1): 66. https://doi.org/10.3390/pharmaceutics12010066.
[37] Mukprasirt A, Domrongpokkaphan V, Kaewpanya L, Khemkhao M, Sumonsiri N. Factors affecting the production of synbiotic fermented milk tablets containing jerusalem artichoke powder and Lacticaseibacillus casei TISTR 1463. J Food Process Preserv. 2022; 46(1): 1-12. https://doi.org/10.1111/jfpp.16153.
[38] Xu Y, Zhao H, Yan X, Zhao S. Preparation of a probiotic rice tablet: Sensory evaluation and antioxidant activity during gastrointestinal digestion. LWT- Food Sci Technol. 2020; 124: 108911. https://doi.org/10.1016/j.lwt.2019.108911.
[39] Chen H, Tian M, Chen L, Cui X, Meng J, Shu G. Optimization of composite cryoprotectant for freeze-drying Bifidobacterium bifidum BB01 by response surface methodology. Artif Cells Nanomed Biotechnol. 2019; 47(1): 1559–1569. https://doi.org/10.1080/21691401.2019.1603157.
[40] Shu G, Tian M, Chen L, Ma D, Cui X, Meng J. Probiotic goat milk tablets: Formulation optimization and stability evaluation. LWT- Food Sci Technol. 2020; 119: 108862. https://doi.org/10.1016/j.lwt.2019.108862.
[41] Çaglar E, Cildir SK, Ergeneli S, Sandalli N, Twetman S. Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets. Acta Odontol Scand. 2006; 64(5): 314–318. https://doi.org/10.1080/00016350600801709.
[42] Chuang LC, Huang CS, Ou-Yang LW, Lin SY. Probiotic Lactobacillus paracasei effect on cariogenic bacterial flora. Clin Oral Investig. 2011; 15(4): 471–476. https://doi.org/10.1007/s00784-010-0423-9.
[43] Iniesta M, Herrera D, Montero E, Zurbriggen M, Matos AR, Marín MJ, Sánchez-Beltrán MC, Llama-Palacio A, Sanz M. Probiotic effects of orally administered Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. J Clin Periodontol. 2012; 39(8): 736–744. https://doi.org/10.1111/j.1600-051X.2012.01914.x.
[44] Han HS, Yum H, Cho YD, Kim S. Improvement of halitosis by probiotic bacterium Weissella cibaria CMU: A randomized controlled trial. Front Microbiol. 2023; 14: 1108762. https://doi.org/10.3389/fmicb.2023.1108762.
[45] Huang F, Li S, Chen W, Han Y, Yao Y, Yang L, Li Q, Xiao Q, Wei J, Liu Z, Chen T, Deng X. Postoperative probiotics administration attenuates gastrointestinal complications and gut microbiota dysbiosis caused by chemotherapy in colorectal cancer patients. Nutrients. 2023; 15(2): 356. https://doi.org/10.3390/nu15020356.
[46] Bose S, Das R, Nandi P, Raavi S, Bhasme S, Boruah B. Preparation and evaluation of probiotic chewable tablets. Int J Curr Res. 2021; 13(06): 17702–17705. https://doi.org/10.24941/ijcr.41573.06.2021.
[47] Gawade NL, Shendge RS. A review on chewable tablet. J Emerg Technol Innov Res. 2020; 7(3): 342–353.
[48] Nyamweya NN, Kimani SN. Chewable tablets: A review of formulation considerations. Pharm Technol. 2020; 44(11): 38–44.
[49] Chan YL, Jamalullail NA, Tan CP, Abdul Manap MY, Lai OM. Development of bio-yoghurt chewable tablet: a review. Nutr Food Sci. 2020; 50(3): 539–553. https://doi.org/10.1108/NFS-07-2019-0202.
[50] FDA. Quality Attribute Considerations for Chewable Tablets Guidance for Industry Quality Attribute Considerations for Chewable Tablets Guidance for Industry. 2018. https://www.fda.gov/files/drugs/published/Quality-Attribute-Considerations-for-Chewable-Tablets-Guidance-for-Industry.pdf, (accessed August 25, 2023).
[51] Hedayati-Hajikand T, Lundberg U, Eldh C, Twetman S. Effect of probiotic chewing tablets on early childhood caries – a randomized controlled trial. BMC Oral Health. 2015; 15: 112. https://doi.org/10.1186/s12903-015-0096-5.
[52] Cannon M, Trent B, Vorachek A, Kramer S, Esterly R. Effectiveness of CRT at measuring the salivary level of bacteria in caries prone children with probiotic therapy. J Clin Pediatr Dent. 2013; 38(1): 55–60. https://doi.org/10.17796/jcpd.38.1.b481624264142082.
[53] Çaglar E, Topcuoglu N, Çildir SK, Sandalli N, Kulekci G. Oral colonization by Lactobacillus reuteri ATCC 55730 after exposure to probiotics. Int J Paediatr Dent. 2009; 19(5): 377–381. https://doi.org/10.1111/j.1365-263X.2009.00989.x.
[54] Shetty S, Khan DKM, Khayat MMN, Hakami SA, Alsaadawi LS, Alsibale DB. Clinical evaluation of chewable probiotic tablets as an adjunct to non-surgical periodontal therapy in the treatment of periodontal disease- A pilot project. J Coast Life Med. 2023; 1(11): 3092–3104. https://www.jclmm.com/index.php/journal/article/view/803.
[55] Sireswar S, Ghosh I, Dey G. First and second generation probiotic therapeutics for inflammatory bowel disease. PharmaNutrition. 2019; 9: 100159. https://doi.org/10.1016/j.phanu.2019.100159.
[56] Song M, Yun B, Moon JH, Park DJ, Lim K, Oh S. Characterization of selected Lactobacillus strains for use as probiotics. Korean J Food Sci Anim Resour. 2015; 35(4): 551-556. https://doi.org/10.5851/kosfa.2015.35.4.551.
[57] Khaneghah AM, Abhari K, Eş I, Soares MB, Oliveira RBA, Hosseini H, Rezaei M, Balthazar CF, Cruz AG, Ranadheera S, Sant'Ana AS. Interactions between probiotics and pathogenic microorganisms in hosts and foods: A review. Trends Food Sci Technol. 2020; 95: 205–218. https://doi.org/10.1016/j.tifs.2019.11.022.
[58] Li T, Teng D, Mao R, Hao Y, Wang X, Wang J. A critical review of antibiotic resistance in probiotic bacteria. Int Food Res J. 2020; 136: 109571. https://doi.org/10.1016/j.foodres.2020.109571.
[59] Altun HK, Yıldız EA, Akın M. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study. Turk J Gastroenterol. 2019; 30(4): 313–320. https://doi.org/10.5152/tjg.2019.18356.
[60] Spielholz C. Efficacy of a synbiotic chewable tablet in the prevention of antibiotic-associated diarrhea. Health. 2011; 03(02): 110–115. https://doi.org/10.4236/health.2011.32020.
[61] Sudha MR, Jayanthi N, Aasin M, Dhanashri RD, Anirudh T. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: A double blind, randomised placebo controlled study. Benef Microbes. 2018; 9(4): 563–572. https://doi.org/10.3920/BM2017.0129.
[62] Gan D, Chen J, Tang X, Xiao L, Martoni CJ, Leyer G, Huang G, Li W. Impact of a probiotic chewable tablet on stool habits and microbial profile in children with functional constipation: A randomized controlled clinical trial. Front Microbiol. 2022; 13: 985308. https://doi.org/10.3389/fmicb.2022.985308.
[63] Lehtoranta L, Kalima K, He L, Lappalainen M, Roivainen M, Närkiö M, Mäkelä M, Siitonen S, Korpela R, Pitkäranta A. Specific probiotics and virological findings in symptomatic conscripts attending military service in Finland. J Clin Virol. 2014; 60(3): 276–281. https://doi.org/10.1016/j.jcv.2014.03.021.
[64] Ahmed M, Billoo AG, Iqbal K. Efficacy of probiotic in perennial allergic rhinitis undefive year children: A randomized controlled trial. Pak J Med Sci. 2019; 35(6): 1538–1543. https://doi.org/10.12669/pjms.35.6.744.
[65] Patel SG, Siddaiah M. Formulation and evaluation of effervescent tablets: a review. J Drug Deliv Ther. 2018; 8(6): 296–303. https://doi.org/10.22270/jddt.v8i6.2021.
[66] Bharat WT, Umesh TJ, Vinod MT, Leena RB. Formulation and evaluation of diclofenac sodium effervescent tablet. Innov Pharm Technol. 2014; 2(2): 350–358.
[67] Chaiya P, Okonogi S, Phaechamud T. Stereomicroscope with imaging analysis: A versatile tool for wetting, gel formation and erosion rate determinations of eutectic effervescent tablet. Pharmaceutics. 2022; 14(1280): 1–19. https://doi.org/10.3390/pharmaceutics14061280.
[68] Dubray C, Maincent P, Milon JY. From the pharmaceutical to the clinical: The case for effervescent paracetamol in pain management. A narrative review. Curr Med Res Opin. 2021; 37(6): 1039–1048. https://doi.org/10.1080/03007995.2021.1902297.
[69] Srinath KR, Chowdary CP, Palanisamy P, Vamsy KA, Aparna S, Ali SS, Rakesh P, Swetha K. Formulation and evaluation of effervescent tablets of paracetamol. Int J Pharm Res Dev. 2011; 3(3): 76–104.
[70] Aslani A, Jahangiri H. Formulation, characterization and physicochemical evaluation of ranitidine effervescent tablets. Adv Pharm Bull. 2013; 3(2): 315–322. https://doi.org/10.5681/apb.2013.051.
[71] Aslani A, Fattahi F. Formulation, characterization and physicochemical evaluation of potassium citrate effervescent tablets. Adv Pharm Bull. 2013; 3(1): 217–225. https://doi.org/10.5681/apb.2013.036.
[72] Thoke SB, Sharma YP, Rawat SS, Satish NL. Formulation development & evaluation of effervescent tablet of alendronate sodium with vitamin D3. J Drug Deliv Ther. 2013; 3(5): 65-74. https://doi.org/10.22270/jddt.v3i5.623.
[73] Nagashima AI, Pansiera PE, Baracat MM, Gómez RJHC. Development of effervescent products, in powder and tablet form, supplemented with probiotics Lactobacillus acidophilus and Saccharomyces boulardii. Food Sci Technol. 2013; 33(4): 605–611. https://doi.org/10.1590/S0101-20612013000400002.
[74] Ngatirah N, Syaflan M, N SA. Effect of Iles-Iles (Amorphophallus oncophyllus) synbiotic effervescent tablet to decrease in blood sugar levels in hyperglycemic white rat (Rattus norvegicus). In: 10th Asian Conference of Lactic Acid Bacteria. UGM Press; 2020. https://doi.org/10.29037/digitalpress.22330.
[75] Hoffmann A, Fischer JT, Daniels R. Development of probiotic orodispersible tablets using mucoadhesive polymers for buccal mucoadhesion. Drug Dev Ind Pharm. 2020; 46(11): 1753–1762. https://doi.org/10.1080/03639045.2020.1831013.
[76] Hoffmann A, Daniels R. Ultra–fast disintegrating ODTs comprising viable probiotic bacteria and HPMC as a mucoadhesive. Eur J Pharm Biopharm. 2019; 139: 240–245. https://doi.org/10.1016/j.ejpb.2019.03.022.
[77] Comoglu T, Ozyilmaz DE. Orally disintegrating tablets and orally disintegrating mini tablets–novel dosage forms for pediatric use. Pharm Dev Technol. 2019; 24(7): 902–914. https://doi.org/10.1080/10837450.2019.1615090.
[78] Kim J, Muhammad N, Jhun BH, Yoo JW. Probiotic delivery systems: A brief overview. J Pharm Investig. 2016; 46: 377–386. https://doi.org/10.1007/s40005-016-0259-7.
[79] Rather SA, Akhter R, Masoodi FA, Gani A, Wani SM. Effect of double alginate microencapsulation on in vitro digestibility and thermal tolerance of Lactobacillus plantarum NCDC201 and L. casei NCDC297. J Food Technol. 2017; 83: 50–58. https://doi.org/10.1016/j.lwt.2017.04.036.
[80] Park HJ, Lee GH, Jun J, Son M, Kang MJ. Multiple-unit tablet of probiotic bacteria for improved storage stability, acid tolerability, and in vivo intestinal protective effect. Drug Des Devel Ther. 2016; 10: 1355–1364. https://doi.org/10.2147/DDDT.S103894.
[81] Qin XS, Luo ZG, Li XL. An enhanced pH-sensitive carrier based on alginate-Ca-EDTA in a set-type W1/O/W2 double emulsion model stabilized with WPI-EGCG covalent conjugates for probiotics colon-targeted release. Food Hydrocoll. 2021; 113: 106460. https://doi.org/10.1016/j.foodhyd.2020.106460.
[82] Govender M, Choonara YE, van Vuuren S, Kumar P, du Toit LC, Pillay V. A gastro-resistant ovalbumin bi-layered mini-tablet-in-tablet system for the delivery of Lactobacillus acidophilus probiotic to simulated human intestinal and colon conditions. J Pharm Pharmacol. 2015; 67(7): 939–950. https://doi.org/10.1111/jphp.12389.
[83] Arepally D, Goswami TK. Effect of inlet air temperature and gum Arabic concentration on encapsulation of probiotics by spray drying. LWT-Food Sci Technol. 2019; 99: 583–593. https://doi.org/10.1016/j.lwt.2018.10.022.
[84] Venema K, Verhoeven J, Verbruggen S, Espinosa L, Courau S. Probiotic survival during a multi-layered tablet development as tested in a dynamic, computer-controlled in vitro model of the stomach and small intestine (TIM-1). Lett Appl Microbiol. 2019; 69(5): 325–332. https://doi.org/10.1111/lam.13211.
[85] Villena MJM, Lara-Villoslada F, Martínez MAR, Hernández MEM. Development of gastro-resistant tablets for the protection and intestinal delivery of Lactobacillus fermentum CECT 5716. Int J Pharm. 2015; 487(1–2): 314–319. https://doi.org/10.1016/j.ijpharm.2015.03.078.
[86] Huq T, Vu KD, Riedl B, Bouchard J, Han J, Lacroix M. Development of probiotic tablet using alginate, pectin, and cellulose nanocrystals as excipients. Cellulose. 2016; 23(3): 1967–1978. https://doi.org/10.1007/s10570-016-0905-2.
[87] Kim WS, Cho CS, Hong L, Han GG, Kil BJ, Kang SK, Kim DD, Choi YJ, Huh CS. Oral delivery of probiotics using pH-sensitive phthalyl inulin tablets. J Microbiol Biotechnol. 2019; 29(2): 200–208. https://doi.org/10.4014/jmb.1811.11021.
[88] Azhar MA, Munaim MSA. Design and optimization of a probiotic tablet for gastrointestinal tolerance by a simplex-centroid mixture. Drug Dev Ind Pharm. 2021; 47(2): 189–196. https://doi.org/10.1080/03639045.2020.1862176.
[89] Vorländer K, Bahlmann L, Kwade A, Finke JH, Kampen I. Effect of Process Parameters, Protectants and Carrier Materials on the Survival of Yeast Cells during Fluidized Bed Granulation for Tableting. Pharmaceutics. 2023; 15(3): 884. https://doi.org/10.3390/pharmaceutics15030884.
[90] Vorländer K, Pramann P, Kwade A, Finke JH, Kampen I. Process and formulation parameters influencing the survival of Saccharomyces cerevisiae during spray drying and tableting. Int J Pharm. 2023; 642: 123100. https://doi.org/10.1016/j.ijpharm.2023.123100

Details

Primary Language

English

Subjects

Pharmaceutical Delivery Technologies

Journal Section

Review

Authors

Buse Kandur This is me
0009-0004-9526-3344
Türkiye

Timuçin Uğurlu
0000-0002-8874-5941
Türkiye

Erkan Rayaman
0000-0002-1261-3942
Türkiye

Sevinç Şahbaz
0000-0001-9195-5563
Türkiye

Publication Date

June 28, 2025

Submission Date

June 1, 2023

Acceptance Date

August 26, 2023

Published in Issue

Year 2024 Volume: 28 Number: 1

IZ

https://izlik.org/JA53WP36XE

Cite

RIS / Bibtex

APA

Kandur, B., Uğurlu, T., Rayaman, E., & Şahbaz, S. (2025). Oral pharmabiotic tablet formulations. Journal of Research in Pharmacy, 28(1), 236-247. https://izlik.org/JA53WP36XE

AMA

1.Kandur B, Uğurlu T, Rayaman E, Şahbaz S. Oral pharmabiotic tablet formulations. J. Res. Pharm. 2025;28(1):236-247. https://izlik.org/JA53WP36XE

Chicago

Kandur, Buse, Timuçin Uğurlu, Erkan Rayaman, and Sevinç Şahbaz. 2025. “Oral Pharmabiotic Tablet Formulations”. Journal of Research in Pharmacy 28 (1): 236-47. https://izlik.org/JA53WP36XE.

EndNote

Kandur B, Uğurlu T, Rayaman E, Şahbaz S (June 1, 2025) Oral pharmabiotic tablet formulations. Journal of Research in Pharmacy 28 1 236–247.

IEEE

[1]B. Kandur, T. Uğurlu, E. Rayaman, and S. Şahbaz, “Oral pharmabiotic tablet formulations”, J. Res. Pharm., vol. 28, no. 1, pp. 236–247, June 2025, [Online]. Available: https://izlik.org/JA53WP36XE

ISNAD

Kandur, Buse - Uğurlu, Timuçin - Rayaman, Erkan - Şahbaz, Sevinç. “Oral Pharmabiotic Tablet Formulations”. Journal of Research in Pharmacy 28/1 (June 1, 2025): 236-247. https://izlik.org/JA53WP36XE.

JAMA

1.Kandur B, Uğurlu T, Rayaman E, Şahbaz S. Oral pharmabiotic tablet formulations. J. Res. Pharm. 2025;28:236–247.

MLA

Kandur, Buse, et al. “Oral Pharmabiotic Tablet Formulations”. Journal of Research in Pharmacy, vol. 28, no. 1, June 2025, pp. 236-47, https://izlik.org/JA53WP36XE.

Vancouver

1.Buse Kandur, Timuçin Uğurlu, Erkan Rayaman, Sevinç Şahbaz. Oral pharmabiotic tablet formulations. J. Res. Pharm. [Internet]. 2025 Jun. 1;28(1):236-47. Available from: https://izlik.org/JA53WP36XE